

Anti-DcR1 (ED) *TRAIL-R3, TRID, LIT*

CATALOG No.: PX052A
PX052B

SIZE: 100 µg
0.5 mg

BACKGROUND:

Apoptosis is induced by certain cytokines including TNF and Fas ligand in the TNF family through their death domain containing receptors. TRAIL/Apo2L is a new member of the TNF family and induces apoptosis of a variety of tumor cell lines. DR4 and DR5 are the recently identified functional receptors for TRAIL (1-3). Two decoy receptors for TRAIL have been identified and designated DcR1/TRID/TRAIL-R3/LIT (2-7) and DcR2/TRAIL-R4/TRUNDD (8-10). DcR1 has extracellular TRAIL-binding domain but lacks intracellular signaling domain. It is a glycosphospholipid-anchored cell surface protein. DcR1 transcripts were expressed in many normal human tissues but not in most cancer cell lines (2,3). Overexpression of DcR1 did not induce apoptosis, but attenuated TRAIL-induced apoptosis (2,3).

SOURCE:


Rabbit anti-DcR1 (ED) polyclonal antibody was raised against a peptide corresponding to amino acids 149 to 167 at extracellular domain (ED) of human DcR1 precursor (2-3).

APPLICATION:

This polyclonal antibody can be used for detection of DcR1 by Western blot at 1:500 to 1:1000 dilution. HeLa cell lysate can be used as positive control and an approximate 65 kDa band can be detected (6). It is human, mouse, and rat reactive. For research use only.

STORAGE:

It is supplied as chromatography purified IgG, 100 µg in 200 µl of PBS containing 0.02% sodium azide. Store at -20°C. Stable for one year at 2-8°C.



Western blot analysis of DcR1 in HeLa whole cell lysate with anti-DcR1 (ED) at 1:500 dilution.

REFERENCES:

1. Pan G; O'Rourke K; Chinnaiyan et al.. The receptor for the cytotoxic ligand TRAIL. *Science*; 1997;276:111-113
2. Pan G, Ni J, Wei YF, et al. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. *Science* 1997;277:815-8
3. Sheridan JP, Marsters SA, Pitti RM, et al. A. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. *Science* 1997;277:818-21
4. Degli-Esposti MA, Smolak PJ, Walczak H, et al, Smith CA. Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. *J Exp Med* 1997;186(7):1165-70
5. MacFarlane M, Ahmad M, Srinivasula SM, et al. Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL. *J Biol Chem* 1997;272(41):25417-20
6. Schneider P, Bodmer JL, Thome M, Hofmann K, Holler N, Tschopp J. Characterization of two receptors for TRAIL. *FEBS Lett* 1997;416(3):329-34
7. Mongkolsapaya J, Cowper AE, Xu XN, et al. Lymphocyte inhibitor of TRAIL (TNF-related apoptosis-inducing ligand): a new receptor protecting lymphocytes from the death ligand TRAIL. *J Immunol* 1998;160(1):3-6
8. Marsters SA, Sheridan JP, Pitti RM, et al. A novel receptor for Apo2L/TRAIL contains a truncated death domain. *Curr Biol* 1997;7:1003-6
9. Degli-Esposti MA, Dougall WC, Smolak PJ, et al. The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. *Immunity* 1997;7:813-20
10. Pan G, Ni J, Yu G, et al. TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signalling. *FEBS Lett* 1998;424:41-5

CAUTION: NOT FOR USE IN HUMANS. FOR RESEARCH PURPOSES ONLY.



Cell Sciences, Inc.
480 Neponset Street
Bldg 12A
Canton, MA 02021

Toll Free: 888-769-1246
Phone: 781-828-0610
Fax: 781-828-0542

E-mail: info@cellsciences.com
Web Site: www.cellsciences.com